Litcius/Paper detail

383O MAYA trial: Temozolomide (TMZ) priming followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite stable (MSS), MGMT silenced metastatic colorectal cancer (mCRC)

Filippo Pietrantonio, Federica Morano, Sara Lonardi, Alessandra Raimondi, Lisa Salvatore, Federica Marmorino, Sabina Murgioni, Nicoletta Pella, Lorenzo Antonuzzo, Giuliana Ritorto, Alberto Zaniboni, Margherita Ratti, Federica Palermo, Filippo Pagani, Michele Prisciandaro, Celeste Cagnazzo, Iolanda Capone, Massimo Milione, Maria Di Bartolomeo, Filippo de Braud

2021Annals of Oncology17 citationsDOI

Topics & Concepts

MedicineTemozolomideNivolumabIpilimumabOncologyColorectal cancerInternal medicineDacarbazineCancerChemotherapyImmunotherapyColorectal Cancer Treatments and StudiesCancer Genomics and DiagnosticsCancer Immunotherapy and Biomarkers